5c), including retinopathy (95% CI: 11.93, 9.1615.54), ischemic optic neuropathy (95% CI: 9.15, 6.3813.12), diabetic ophthalmopathy (95% CI: 7.84, 2.9321.01), diabetic retinal edema (95% CI: 6.42, 2.4017.18), and retinal rupture (95% CI: 4.39, 2.547.57)
The role of SeekPeptides in your GLP-1 journey Navigating GLP-1 medication decisions, from understanding why semaglutide failed to evaluating whether tirzepatide is the right next step, requires reliable, evidence-based information
Semaglutide : FDA-approved since 2017 for T2D, 2021 for obesity
If you're interested in exploring whether sublingual semaglutide might be appropriate for your weight management goals, our team can work alongside your current provider or help connect you with a consultation
Tirzepatide does all of that, plus two more things through GIP receptor activation
Yun SP, Kam TI, Panicker N, Kim S, Oh Y, Park JS, et al